



39766-0073 A2

P1801 R2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	: Erickson <i>et al.</i>) Examiner:	A. HOLLERAN
Appl. No.	: 09/811,123) Group Art Unit:	1642
Filed	: March 16, 2001) Confirmation Number:	6508
For	: METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY MAYTANSINOID CONJUGATES) STATEMENT	

STATEMENT OF WALTER A. BLATTLER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

I, Walter Blattler, hereby say as follows:

1. I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY MAYTANSINOID CONJUGATES**; the specification of which was filed on **March 16, 2001** as Application Serial No. **09/811,123**.

2. My name was not included in the filing papers of Application Serial No. **09/811,123** as originally filed.

3. The omission of my name from the filing papers of Application Serial No. **09/811,123** as originally filed was without deceptive intent on my part.

4. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Date: Nov. 13, 2003By: W. Blattler

Walter A. Blattler

*Kim,
Please send out
corrected
filing receipt to
add inventor
Walter Blattler.*



39766-0073 A2

P1801 R2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Erickson <i>et al.</i>)	Examiner:	A. HOLLERAN
Appl. No.	:	09/811,123)	Group Art Unit:	1642
Filed	:	March 16, 2001)	Confirmation Number:	6508
For	:	METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY MAYTANSINOID CONJUGATES)		STATEMENT

CONSENT OF ASSIGNEE TO CHANGE INVENTORSHIP

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Assignee consents to correction of inventorship of the application entitled **METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY MAYTANSINOID CONJUGATES**; the specification of which was filed on **March 16, 2001** as Application Serial No. **09/811,123** to reflect the following named inventors:

- | | |
|--------------------|-----------------------|
| 1. Sharon Erickson | 3. Mark Sliwkowski |
| 2. Ralph Schwall | 4. Walter A. Blattler |

Please charge any additional fees, including fees for extension of time, or credit overpayment to Deposit Account 08-1641 referencing Attorney Docket No. 39766-0073 A2.

The undersigned has authority to sign for the assignee GENENTECH, INC. whose interest in the above-identified application was recorded at Reel 012132 and Frame 0897 on September 10, 2001.

duE

Date: November 21, 2003 By: Sean Johnston
Sean A. Johnston
Vice President, Intellectual Property
Genentech, Inc.



39766-0073 A2

P1801 R2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	: Erickson <i>et al.</i>)	Examiner:	A. HOLLERAN
Appl. No.	: 09/811,123)	Group Art Unit:	1642
Filed	: March 16, 2001)	Confirmation Number:	6508
For	: METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY MAYTANSINOID CONJUGATES)	STATEMENT	

CONSENT OF ASSIGNEE TO CHANGE INVENTORSHIP

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Assignee consents to correction of inventorship of the application entitled **METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY MAYTANSINOID CONJUGATES**; the specification of which was filed on **March 16, 2001** as Application Serial No. **09/811,123** to reflect the following named inventors:

- | | |
|--------------------|-----------------------|
| 1. Sharon Erickson | 3. Walter Sliwkowski |
| 2. Ralph Schwall | 4. Walter A. Blattler |

Please charge any additional fees, including fees for extension of time, or credit overpayment to Deposit Account 08-1641 referencing Attorney Docket No. 39766-0073 A2.

The undersigned has authority to sign for the assignee IMMUNOGEN, INC. whose interest in the above-identified application was recorded at Reel 013566 and Frame 0732 on April 4, 2003.

Date: 11/17/03By: 

Gregg Beloff

Vice President and Chief Financial Officer
ImmunoGen, Inc.